ConductScience.org, home

Trial · NCT04647110

Results by group204

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Duration of Treatment: Based on Treatment Cohort GroupsGroup A11.66Standard Deviation 1.28Years
Duration of Treatment: Based on Treatment Cohort GroupsGroup A21.86Standard Deviation 1.31Years
Duration of Treatment: Based on Treatment Cohort GroupsGroup B13.37Standard Deviation 1.24Years
Duration of Treatment: Based on Treatment Cohort GroupsGroup B22.45Standard Deviation 1.53Years
Duration of Treatment: Based on Treatment Cohort GroupsGroup C12.56Standard Deviation 1.42Years
Duration of Treatment: Based on Treatment Cohort GroupsGroup C22.72Standard Deviation 1.03Years
Duration of Treatment: Based on Treatment Cohort GroupsGroup D11.36Standard Deviation 0.75Years
Duration of Treatment: Based on Chemotherapy StatusParticipants With No First Line Chemotherapy1.23Standard Deviation 1.28Years
Duration of Treatment: Based on Chemotherapy StatusParticipants With First Line Chemotherapy1.07Standard Deviation 1.28Years
Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI TreatmentCrizotinibFirst Line ALK TKI Treatment Duration0.72Standard Deviation 1.19Years
Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI TreatmentAlectinibFirst Line ALK TKI Treatment Duration0.92Standard Deviation 0.82Years
Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI TreatmentCeritinibFirst Line ALK TKI Treatment DurationNAStandard Deviation NAYears
Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI TreatmentCrizotinib + ChemotherapyFirst Line ALK TKI Treatment Duration0.50Standard Deviation 0.80Years
Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI TreatmentAlectinib + ChemotherapyFirst Line ALK TKI Treatment Duration0.80Standard Deviation 0.88Years
Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI TreatmentCeritinib + ChemotherapyFirst Line ALK TKI Treatment Duration1.01Standard Deviation 1.23Years
Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI TreatmentCrizotinibTotal Sequence Treatment Duration0.72Standard Deviation 1.19Years
Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI TreatmentAlectinibTotal Sequence Treatment Duration0.92Standard Deviation 0.82Years
Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI TreatmentCeritinibTotal Sequence Treatment DurationNAStandard Deviation NAYears
Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI TreatmentCrizotinib + ChemotherapyTotal Sequence Treatment Duration0.50Standard Deviation 0.80Years
Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI TreatmentAlectinib + ChemotherapyTotal Sequence Treatment Duration0.80Standard Deviation 0.88Years

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04647110/results